Microcore has more than two decades of experiences in research, manufacturing and scale up of many Nutrabioceuticals and Therapeutics. Saccharomyces boulardii is a probiotic, non-pathogenic yeast widely used to support gastrointestinal health. It is unique because, unlike bacterial probiotics, it does not colonize the gut permanently and is unaffected by antibiotics, making it especially useful during antibiotic therapy.
Clinically, S. boulardii has been shown to help reduce diarrhea, restore healthy intestinal microflora, and alleviate symptoms such as abdominal pain and increased stool frequency. Its long history of safe use and strong clinical evidence makes it a trusted probiotic for both adults and children.
Clinically proven probiotic yeast with strong evidence from genomic, pre-clinical, and clinical studies supporting safety and efficacy. Helps restore healthy intestinal microflora, especially after infections, antibiotic use, or digestive disturbances. Effective in reducing diarrhea, including antibiotic-associated diarrhea (AAD), travelers diarrhea, and infectious diarrhea. Unaffected by antibiotics because it is a yeast, making it ideal for concurrent use during antibiotic therapy. Supports overall gastrointestinal health by reducing inflammation, improving gut barrier function, and normalizing bowel movements. Non-colonizing and transient, meaning it works while passing through the GI tract without permanently altering gut composition. Safe for adults and children, with over 50 years of global clinical use
Saccharomyces boulardii is widely used for comprehensive gastrointestinal support, particularly in managing diarrhea, including antibiotic associated, traveler's, and acute infectious diarrhea in both adults and children. It effectively helps restore healthy gut flora after antibiotic therapy and serves as supportive care in inflammatory conditions such as IBS and IBD.
Beyond human health, it is also used in veterinary applications for digestive support and diarrhea prevention in pets such as dogs, cats, and horses.
MRL 1019 Saccharomyces boulardii offers multiple clinical advantages: naturally survives harsh gastric conditions (stomach acid and bile), unaffected by antibiotics, acts rapidly in managing diarrhea, and inhibits the adhesion of harmful pathogens such as E. coli, C. difficile, and Salmonella. It is highly stable and shelf-resistant compared to many bacterial probiotics.
Saccharomyces boulardii strengthens the gut's immune defense by increasing secretory IgA (sIgA) through activation of immune cells in the Peyer's patches. The rise in sIgA helps bind and block pathogens and toxins. It also stimulates the production of specific anti-toxin antibodies against harmful bacterial toxins such as C. difficile toxins A and B and E. coli heat-labile toxin.
The developments are at lab scale and expected to complete clinical studies and further launch by 2028.